<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.ukri.org:80/organisation/5A393419-8F67-4FB5-9D17-B9A04A7B3CA9"><gtr:id>5A393419-8F67-4FB5-9D17-B9A04A7B3CA9</gtr:id><gtr:name>University of New South Wales</gtr:name><gtr:address><gtr:line1>Gate 9 High St</gtr:line1><gtr:line2>Kensington</gtr:line2><gtr:line4>Sydney</gtr:line4><gtr:line5>NSW 2052</gtr:line5><gtr:postCode>2052</gtr:postCode><gtr:region>Outside UK</gtr:region><gtr:country>Australia</gtr:country></gtr:address></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/4A348A76-B2D0-4DDD-804A-CE735A6D3798"><gtr:id>4A348A76-B2D0-4DDD-804A-CE735A6D3798</gtr:id><gtr:name>University of Bristol</gtr:name><gtr:department>Physiology and Pharmacology</gtr:department><gtr:address><gtr:line1>Senate House</gtr:line1><gtr:line4>Bristol</gtr:line4><gtr:line5>Avon</gtr:line5><gtr:postCode>BS8 1TH</gtr:postCode><gtr:region>South West</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/4A348A76-B2D0-4DDD-804A-CE735A6D3798"><gtr:id>4A348A76-B2D0-4DDD-804A-CE735A6D3798</gtr:id><gtr:name>University of Bristol</gtr:name><gtr:address><gtr:line1>Senate House</gtr:line1><gtr:line4>Bristol</gtr:line4><gtr:line5>Avon</gtr:line5><gtr:postCode>BS8 1TH</gtr:postCode><gtr:region>South West</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/5A393419-8F67-4FB5-9D17-B9A04A7B3CA9"><gtr:id>5A393419-8F67-4FB5-9D17-B9A04A7B3CA9</gtr:id><gtr:name>University of New South Wales</gtr:name><gtr:address><gtr:line1>Gate 9 High St</gtr:line1><gtr:line2>Kensington</gtr:line2><gtr:line4>Sydney</gtr:line4><gtr:line5>NSW 2052</gtr:line5><gtr:postCode>2052</gtr:postCode><gtr:region>Outside UK</gtr:region><gtr:country>Australia</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/293E79B5-62B2-4618-AFEB-6A06164BDB16"><gtr:id>293E79B5-62B2-4618-AFEB-6A06164BDB16</gtr:id><gtr:firstName>Sebastian</gtr:firstName><gtr:surname>Oltean</gtr:surname><gtr:roles><gtr:role><gtr:name>RESEARCHER_COI</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/CB9FEA1F-8BD2-4560-9CD4-371BBEEFDE7D"><gtr:id>CB9FEA1F-8BD2-4560-9CD4-371BBEEFDE7D</gtr:id><gtr:firstName>David</gtr:firstName><gtr:surname>Bates</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=BB%2FJ007293%2F1"><gtr:id>C959AF1D-473D-43E2-B6A8-E5D4DCCC2B37</gtr:id><gtr:title>Regulation of VEGF splicing</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>BB/J007293/1</gtr:grantReference><gtr:abstractText>Vascular Endothelial Growth Factor is fundamental regulator of blood vessel growth (angiogenesis). It is responsible for blood vessel growth in all tissues in human development from the embryo to the newborn child. It is also key to growth of tissues as children develop into adults, and in adults it is necessary in normal physiology during tissue remodelling (e..g in muscle growth in response to exercise) and in many diseases including cancer, diabetes and heart disease . Over the last three years, our research group has discovered that the way that cells edit together the message encoded by the gene that codes for the most important growth factor for blood vessels (called VEGF) results in two different families of proteins called VEGFxxx and VEGFxxxb. The VEGFxxxb family is widely expressed in normal human tissues, but switched off during angiogenesis, when the VEGFxxx family take over. The VEGFxxx family stimulates blood vessel growth, whereas the VEGFxxxb stops vessels growing, and we have recently identified many new functions of this family - they protects cells from injury, stop development of pain, maintain kidney function, and control fertility. It is now clear that this alternative editing (splicing) is controlled by cells, and appears to switch during angiogenesis and other cell stresses. However, little is known about how cells balance expression of the two families of isoforms by regulating splicing of VEGF in normal tissues. This area is beyond the scope of the medical research charities currently supporting our work to find out whether these isoforms can be used to treat cancers, heart disease, diabetes, pain, renal failure and other conditions. This project aims to determine the molecular and cellular pathways that regulate the balance of splicing of the VEGF mRNA. It will identify some of the molecules that control these splicing events, determine the sequences within the VEGF gene that are recognised by splicing factors, and identify how and where this splicing balance alters in live animals. It will do so using a new, cutting edge technology of in vivo splice reporters. These are synthetic DNA sequences that code for green or red proteins depending on which forms are made. These sequences can be used to follow in real time in live cells which way splicing is happening. This is the only way that splicing can be followed within a live single cell in response to treatments, to normal function, or growth or changes in animals. These new sequences are unique to the laboratory in Bristol, and we wish to exploit this advantage over competing groups in the USA to generate advances in scientific understanding from a UK base.</gtr:abstractText><gtr:technicalSummary>VEGF is a fundamental regulator of angiogenesis in all tissues in development and adulthood. VEGF comprises two families of isoforms generated by alternative splicing. VEGFxxx isoforms are pro-angiogenic. In 2002 we identified a sister family of isoforms that are anti-angiogenic, predominate in normal tissues but are down-regulated during angiogenesis when the pro-angiogenic isoforms take over, which has stimulated a program of research in our and other laboratories investigating their role in disease states and normal physiology. They have now been identified as cytoprotective agents for oxidative stress, hyperglycaemia, ischemia and hypoxia. They are anti-nociceptive, control glomerular permeability in the kidney, fertility, mammary development and regulate angiogenesis in physiological states. This alternative splicing is regulated at the cellular level, and switches during the angiogenesis process. We recently identified some of the mechanisms underlying regulation of alternate splicing of VEGF in vitro systems using simple cell treatments and assessment of splicing products. We have identified some sequences in the splice regions that specify splice site choice. This project will identify new molecular and cellular pathways that regulate this alternate splicing in vivo. It will make use of recently developed bichromatic splicing reporter systems to identify the molecular regulators and sequences recognised by these regulators. These reporters offer a unique advantage because they can be used for high throughput screening (e.g. genome wide siRNA screens), can follow splicing in real time in single cell populations (e.g. in circulating cells, or complex organs such as the glomerulus), and can be used to visualise splicing in intact animals. We will use these systems to determine the splicing switches that occur in in vivo physiological systems, by generating transgenic animals that have real time fluorescent bi-chromatic reporter splicing systems.</gtr:technicalSummary><gtr:potentialImpactText>This project will extend our understanding of one of the most basic physiological processes on which multi-cellular, multi-organ organisms depend. The process of developing and extending a vascular infrastructure that ensures appropriate delivery of nutrients to, and removal of toxic metabolites from, the tissues. This will be achieved by investigating the molecular mechanism that determines the VEGF mRNA splicing repertoire and therefore the time and spatially specific proteome that governs a physiological angiogenic phenotype. We will use molecular, cellular and animal models.

The methods utilised and optimised will be applicable to further study of angiogenic situations influenced by VEGF, both in in physiology, such as wound healing, and disease such as malignancy. Allowing detailed analysis of soluble mediators, factors, cytokines and splicing mediators and related drug targets. 

Since over 90% of genes splice, with an average number of 7 isoforms, and since many physiological responses and human diseases depend on angiogenesis our findings may have a broad impact.</gtr:potentialImpactText><gtr:fund><gtr:end>2013-04-07</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/2512EF1C-401B-4222-9869-A770D4C5FAC7"><gtr:id>2512EF1C-401B-4222-9869-A770D4C5FAC7</gtr:id><gtr:name>BBSRC</gtr:name></gtr:funder><gtr:start>2012-04-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>473373</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of New South Wales</gtr:collaboratingOrganisation><gtr:country>Australia, Commonwealth of</gtr:country><gtr:department>School of Chemistry</gtr:department><gtr:description>UNSW</gtr:description><gtr:id>98E1E532-E5E3-495A-82F7-658288BBB21C</gtr:id><gtr:impact>Exonate, spin out company</gtr:impact><gtr:outcomeId>58c17b677348b4.50512616-1</gtr:outcomeId><gtr:partnerContribution>Development of new inhibitors</gtr:partnerContribution><gtr:piContribution>Development of new inhibitors</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs/><gtr:exploitationOutputs/><gtr:furtherFundingOutputs/><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:keyFindingsOutput><gtr:description>A drug screen was undertaken using a sensitive novel reporter screen to pick up new chemical hits that could inhibit blood vessel growth. A number were found and are the subject of further study.
Mice were generated that expressed the reporter gene, and are being used to determine control of splicing in different tissues.</gtr:description><gtr:exploitationPathways>We intend to take these forward as a drug development project.</gtr:exploitationPathways><gtr:id>503AD5E9-9AF9-4040-B696-BEC8C5746D88</gtr:id><gtr:outcomeId>56df32b29c0b32.67601542</gtr:outcomeId><gtr:sectors><gtr:sector>Pharmaceuticals and Medical Biotechnology</gtr:sector></gtr:sectors></gtr:keyFindingsOutput><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Scientific Advisor to the South African MRC</gtr:description><gtr:geographicReach>Africa</gtr:geographicReach><gtr:id>17491DA2-8CE4-4AC3-B214-63018B85DA4C</gtr:id><gtr:outcomeId>56ddc9579af186.35628590</gtr:outcomeId><gtr:type>Participation in a advisory committee</gtr:type></gtr:policyInfluenceOutput></gtr:policyInfluenceOutputs><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs><gtr:researchMaterialOutput><gtr:description>A minigene that can be used to assess VEGF splicing and the dependence of the splicing on teh sequence of the mRNA</gtr:description><gtr:id>8206FB9A-F21D-40EC-85FF-A9B8130C589E</gtr:id><gtr:impact>Identification of the mechanism of binding of SRSF1 to VEGF</gtr:impact><gtr:outcomeId>56df337836ba59.41671433</gtr:outcomeId><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>Minigene</gtr:title><gtr:type>Technology assay or reagent</gtr:type><gtr:yearFirstProvided>2014</gtr:yearFirstProvided></gtr:researchMaterialOutput></gtr:researchMaterialOutputs><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>6DD40409-9F8E-41CE-AD53-27DA5299035D</gtr:id><gtr:title>Hallmarks of glycosylation in cancer.</gtr:title><gtr:parentPublicationTitle>Oncotarget</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/18e4b43f9795107cdf3517838eaafaec"><gtr:id>18e4b43f9795107cdf3517838eaafaec</gtr:id><gtr:otherNames>Munkley J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1949-2553</gtr:issn><gtr:outcomeId>585d3fde02b143.41950831</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>95B57861-C9E0-4316-BE5E-30900A96481C</gtr:id><gtr:title>Screening for anti-angiogenic molecules based on VEGF alternative splicing</gtr:title><gtr:parentPublicationTitle>ANGIOGENESIS</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c4ebd0adea790d48f7fd3021bf0d6345"><gtr:id>c4ebd0adea790d48f7fd3021bf0d6345</gtr:id><gtr:otherNames>Star Eleanor</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0969-6970</gtr:issn><gtr:outcomeId>56dec0cc79e794.27754147</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>051327D2-1168-4DDD-A9FE-22DC2CE74DEF</gtr:id><gtr:title>The Role of Sialyl-Tn in Cancer.</gtr:title><gtr:parentPublicationTitle>International journal of molecular sciences</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/18e4b43f9795107cdf3517838eaafaec"><gtr:id>18e4b43f9795107cdf3517838eaafaec</gtr:id><gtr:otherNames>Munkley J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1422-0067</gtr:issn><gtr:outcomeId>585d7184e9b3f9.35607641</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E84FE9BF-9ABB-4798-B1D9-D23167A3EF1F</gtr:id><gtr:title>Topical antiangiogenic SRPK1 inhibitors reduce choroidal neovascularization in rodent models of exudative AMD.</gtr:title><gtr:parentPublicationTitle>Investigative ophthalmology &amp; visual science</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d8ebe07917c448426c03efb6546f8fd9"><gtr:id>d8ebe07917c448426c03efb6546f8fd9</gtr:id><gtr:otherNames>Gammons MV</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0146-0404</gtr:issn><gtr:outcomeId>pm_13000_20_23887803</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>0E3CD11A-2C85-43CB-9111-0BD33DEDA008</gtr:id><gtr:title>Serine-arginine protein kinase 1 (SRPK1) inhibition as a potential novel targeted therapeutic strategy in prostate cancer.</gtr:title><gtr:parentPublicationTitle>Oncogene</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/1966c872a8a04b1b9fe9d7229ec7e3fd"><gtr:id>1966c872a8a04b1b9fe9d7229ec7e3fd</gtr:id><gtr:otherNames>Mavrou A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0950-9232</gtr:issn><gtr:outcomeId>5675dca609b75</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E8660F13-ACBD-4FFC-9F60-2A97CF635EF6</gtr:id><gtr:title>Serine-arginine protein kinase 1 (SRPK1), a determinant of angiogenesis, is upregulated in prostate cancer and correlates with disease stage and invasion.</gtr:title><gtr:parentPublicationTitle>Journal of clinical pathology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b32060ee92a89b859fd1110c6bbae82d"><gtr:id>b32060ee92a89b859fd1110c6bbae82d</gtr:id><gtr:otherNames>Bullock N</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0021-9746</gtr:issn><gtr:outcomeId>585d743a0aa207.08257471</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>90BBEF21-212E-40C1-BB30-77EB2BE83A2C</gtr:id><gtr:title>VEGF-Ab protects against proteinuria in a mouse model with progressive depletion of all endogenous VEGF-A splice isoforms from the kidney.</gtr:title><gtr:parentPublicationTitle>The Journal of physiology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/183721c90fc07d20966ffda279b321e8"><gtr:id>183721c90fc07d20966ffda279b321e8</gtr:id><gtr:otherNames>Stevens M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0022-3751</gtr:issn><gtr:outcomeId>5a2fcf062bfca4.63864200</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>5C3D30B9-29FD-46E1-9068-B01AB7247AA9</gtr:id><gtr:title>Glycosylation is an Androgen-Regulated Process Essential for Prostate Cancer Cell Viability.</gtr:title><gtr:parentPublicationTitle>EBioMedicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/18e4b43f9795107cdf3517838eaafaec"><gtr:id>18e4b43f9795107cdf3517838eaafaec</gtr:id><gtr:otherNames>Munkley J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>2352-3964</gtr:issn><gtr:outcomeId>585d3516b1c391.73541019</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>708BE202-9C16-40AE-90C6-75B9D9235815</gtr:id><gtr:title>Pharmacology of Modulators of Alternative Splicing.</gtr:title><gtr:parentPublicationTitle>Pharmacological reviews</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/8c09613ef5f756f30f1f8cc349399f83"><gtr:id>8c09613ef5f756f30f1f8cc349399f83</gtr:id><gtr:otherNames>Bates DO</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0031-6997</gtr:issn><gtr:outcomeId>58c1428d4cbb09.96032738</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>87278156-7790-4607-8C53-85F32CC27DF7</gtr:id><gtr:title>Alternative splicing of TIA-1 in human colon cancer regulates VEGF isoform expression, angiogenesis, tumour growth and bevacizumab resistance.</gtr:title><gtr:parentPublicationTitle>Molecular oncology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/bec1957aed31e1c2fd5aedc13db614d2"><gtr:id>bec1957aed31e1c2fd5aedc13db614d2</gtr:id><gtr:otherNames>Hamdollah Zadeh MA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1574-7891</gtr:issn><gtr:outcomeId>5461001330ef62.58139277</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>BADD246B-292F-43A7-9362-94FA75415E95</gtr:id><gtr:title>Vascular Endothelial Growth Factor-A165b Is Protective and Restores Endothelial Glycocalyx in Diabetic Nephropathy.</gtr:title><gtr:parentPublicationTitle>Journal of the American Society of Nephrology : JASN</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/4995fb294220910a61b0946db62ed901"><gtr:id>4995fb294220910a61b0946db62ed901</gtr:id><gtr:otherNames>Oltean S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1046-6673</gtr:issn><gtr:outcomeId>56dd7b7f42d0f1.92078656</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B94A9DBB-3AE1-48BA-97C8-1BA65086E64C</gtr:id><gtr:title>Detection of VEGF-A(xxx)b isoforms in human tissues.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/8c09613ef5f756f30f1f8cc349399f83"><gtr:id>8c09613ef5f756f30f1f8cc349399f83</gtr:id><gtr:otherNames>Bates DO</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn><gtr:outcomeId>pm_13000_20_23935865</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C225F345-F539-4670-B9E6-7969F7916342</gtr:id><gtr:title>Circulating levels of anti-angiogenic VEGF-A isoform (VEGF-Axxxb) in colorectal cancer patients predicts tumour VEGF-A ratios.</gtr:title><gtr:parentPublicationTitle>American journal of cancer research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/0d41de7df9bae253e4f31995db81c234"><gtr:id>0d41de7df9bae253e4f31995db81c234</gtr:id><gtr:otherNames>Bunni J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>2156-6976</gtr:issn><gtr:outcomeId>56dd7b7e759110.04071623</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E4D14895-5BC8-4A02-BD6B-64C0BBDA8EF4</gtr:id><gtr:title>Vascular Endothelial Growth Factor-A165b Restores Normal Glomerular Water Permeability in a Diphtheria-Toxin Mouse Model of Glomerular Injury.</gtr:title><gtr:parentPublicationTitle>Nephron</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/183721c90fc07d20966ffda279b321e8"><gtr:id>183721c90fc07d20966ffda279b321e8</gtr:id><gtr:otherNames>Stevens M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2018-01-01</gtr:date><gtr:issn>1660-8151</gtr:issn><gtr:outcomeId>5a7af78504dfe4.28671424</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>DCD98730-BB70-43EC-8507-F47423E5A062</gtr:id><gtr:title>Targeting SRPK1 to control VEGF-mediated tumour angiogenesis in metastatic melanoma.</gtr:title><gtr:parentPublicationTitle>British journal of cancer</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d8ebe07917c448426c03efb6546f8fd9"><gtr:id>d8ebe07917c448426c03efb6546f8fd9</gtr:id><gtr:otherNames>Gammons MV</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0007-0920</gtr:issn><gtr:outcomeId>5461001356a6f4.26416205</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>CA74BA12-3943-4591-87E1-EE2182E482A3</gtr:id><gtr:title>The androgen receptor controls expression of the cancer-associated sTn antigen and cell adhesion through induction of ST6GalNAc1 in prostate cancer.</gtr:title><gtr:parentPublicationTitle>Oncotarget</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/18e4b43f9795107cdf3517838eaafaec"><gtr:id>18e4b43f9795107cdf3517838eaafaec</gtr:id><gtr:otherNames>Munkley J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1949-2553</gtr:issn><gtr:outcomeId>585d7486d98d18.57266206</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>1C62DF1A-695F-485D-8CB2-9AAEF9B28126</gtr:id><gtr:title>Hallmarks of alternative splicing in cancer.</gtr:title><gtr:parentPublicationTitle>Oncogene</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/4995fb294220910a61b0946db62ed901"><gtr:id>4995fb294220910a61b0946db62ed901</gtr:id><gtr:otherNames>Oltean S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0950-9232</gtr:issn><gtr:outcomeId>54610013832b54.00449570</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>359CF0DE-B352-41BD-B6CA-785C920E9177</gtr:id><gtr:title>The role of glycans in the development and progression of prostate cancer.</gtr:title><gtr:parentPublicationTitle>Nature reviews. Urology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/18e4b43f9795107cdf3517838eaafaec"><gtr:id>18e4b43f9795107cdf3517838eaafaec</gtr:id><gtr:otherNames>Munkley J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1759-4812</gtr:issn><gtr:outcomeId>585d3fdae01152.86775528</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>216DE65A-1237-420F-94FE-ED7613115D95</gtr:id><gtr:title>Using VEGF alternative splicing to screen for antiangiogenic molecule</gtr:title><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/1de1eb0f3ce7aa20eeb3fd1ce8f3f898"><gtr:id>1de1eb0f3ce7aa20eeb3fd1ce8f3f898</gtr:id><gtr:otherNames>EM Star</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:outcomeId>56df2cb7ec9324.36390965</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">BB/J007293/1</gtr:identifier></gtr:identifiers><gtr:projectHierarchy><gtr:parents><gtr:parent><gtr:id>C959AF1D-473D-43E2-B6A8-E5D4DCCC2B37</gtr:id><gtr:grantRef>BB/J007293/1</gtr:grantRef><gtr:amount>473373.84</gtr:amount><gtr:start>2012-04-01</gtr:start><gtr:end>2013-04-07</gtr:end><gtr:children><gtr:child rel="Transfer"><gtr:id>D7A6CD49-9A0F-4DDD-B89C-5B793BC2535E</gtr:id><gtr:grantRef>BB/J007293/2</gtr:grantRef><gtr:amount>334558.84</gtr:amount><gtr:start>2013-04-08</gtr:start><gtr:end>2015-07-31</gtr:end><gtr:children/></gtr:child></gtr:children></gtr:parent></gtr:parents></gtr:projectHierarchy><gtr:healthCategories/><gtr:researchActivities/><gtr:researchSubjects><gtr:researchSubject><gtr:id>17F21DBC-4946-4262-AD07-9914F6EA12F7</gtr:id><gtr:percentage>0</gtr:percentage><gtr:text>Bioengineering</gtr:text></gtr:researchSubject><gtr:researchSubject><gtr:id>C23BE70F-1EF6-4CC7-88B0-841CB18DD875</gtr:id><gtr:percentage>0</gtr:percentage><gtr:text>Genetics &amp; development</gtr:text></gtr:researchSubject><gtr:researchSubject><gtr:id>9BDF80E2-029E-4505-B7EE-DB0FA633E483</gtr:id><gtr:percentage>0</gtr:percentage><gtr:text>Omic sciences &amp; technologies</gtr:text></gtr:researchSubject></gtr:researchSubjects><gtr:researchTopics><gtr:researchTopic><gtr:id>B6EF57B2-8ACD-48E6-9B45-98507446B053</gtr:id><gtr:percentage>0</gtr:percentage><gtr:text>Epigenetics</gtr:text></gtr:researchTopic><gtr:researchTopic><gtr:id>CC10CC12-1D16-48BD-8F66-6A64A651DEAB</gtr:id><gtr:percentage>0</gtr:percentage><gtr:text>Gene action &amp; regulation</gtr:text></gtr:researchTopic><gtr:researchTopic><gtr:id>195B48B4-2BC5-4DEB-BA1A-323A90D8730D</gtr:id><gtr:percentage>0</gtr:percentage><gtr:text>Tissue engineering</gtr:text></gtr:researchTopic><gtr:researchTopic><gtr:id>20FF6FDE-28DB-4D9D-99E6-8470C745EA60</gtr:id><gtr:percentage>0</gtr:percentage><gtr:text>Transcriptomics</gtr:text></gtr:researchTopic></gtr:researchTopics><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>